Drug profile

The FDA adverse-event record for Canine Parvovirus Mab

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Parvovirus Mab. See the species affected, top reactions, and outcomes below.

12
adverse-event reports
75.0%
death-coded share
Dog
most-reported species
9
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
9
Deaths Reported
75.0%
Death Rate

Active Ingredients

Canine Parvovirus Mab

Administration Routes

IntravenousUnknownParenteral

Species Affected

Dog 12

Most Affected Breeds

Poodle (unspecified) 3
Dog (unknown) 2
Collie - Border 2
Shepherd Dog - Belgian Malinois 1
Sheepdog - Shetland 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Coonhound - Bluetick 1
Pointing Dog - German Short-haired 1

Most Reported Reactions

Death 9
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 7
Lateral recumbency 4
Death by euthanasia 3
Unclassifiable adverse event 3
Vomiting 2
Lethargy (see also Central nervous system depression in Neurological) 2
Lack of efficacy - NOS 2
Other abnormal test result NOS 2
Behavioural disorder NOS 2
Diarrhoea 2
Hypoglycaemia 2

Outcome Breakdown

Died
9 (42.9%)
Ongoing
4 (19.0%)
Outcome Unknown
4 (19.0%)
Euthanized
3 (14.3%)
Recovered/Normal
1 (4.8%)

Canine Parvovirus Mab Adverse Event Insights

12 reports name Canine Parvovirus Mab; 9 recorded a death outcome (75.0% of reported events, not a population-level mortality rate). Active ingredient: Canine Parvovirus Mab. Administration routes: Intravenous, Unknown, Parenteral.

By species: Dog (12 reports). By breed: Poodle (unspecified) (3), Dog (unknown) (2), Collie - Border (2).

Leading clinical signs: Death (9), Lack of efficacy (virus) - parvovirus (including feline panleukopenia) (7), Lateral recumbency (4), Death by euthanasia (3). Outcome, 21 coded reports: Died leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.